Enter your keywords

Inhaler Carbon Impact Assessment Tool

Overview The NHS Long Term Plan outlines that 4% of the total NHS carbon footprint savings are expected to be realised through a ‘shift to lower carbon inhalers’ equivalent to a 50% reduction in the inhaler carbon footprint. 1,2 The RDTC has developed an inhaler carbon impact assessment tool in response to these targets. It […]

Price Concessionary Bulletin

The purpose of this bulletin is to present the predicted cost impact of drug price changes, both through the Price Concessions list and also monthly drug tariff (DT) cost variations. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff […]

Items not to be routinely prescribed

This SICBL report is a locality level subsection of the Medicines Optimisation Opportunities Dashboard. It looks at prescribing trends for items and cost, for those items which should not be routinely prescribed in primary care, now termed Low priority prescribing. The NHSE ‘Items which should not be routinely prescribed in primary care’ guidance was originally […]

Respiratory System

This report looks at prescribing trends in primary care for the Respiratory System at SICBL and ICB level with particular focus on bronchodilators and corticosteroids. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for respiratory drugs based on […]

Growth Contrast Tool

Overview The growth contrast tool is intended to help ICBs identify important local effects on prescribing costs. The figures are derived by comparing growth in prescribing costs and items in selected SICBLs with what might have happened if national growth patterns had applied. Comparing actual growth with counterfactuals based on national growth patterns should remove […]

NHS Medicines Optimisation Opportunities Dashboard 2023-24

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]

Drug Tariff Monitor

The purpose of this report is to present the predicted cost impact of category A, M and C drug tariff PartVIIIA price changes on primary care spending. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment […]

Drugs for Dementia

This report looks at prescribing trends in primary care for Drugs for Dementia at SICBL and ICB level with particular focus on low strength antipsychotics. Prescribing data is weighted with QOF registers. If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net Frequency Quarterly Data Period January 2021 to […]

Drugs used in Diabetes

This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBL and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing outcomes. If you have any queries about the content […]

Antibacterial drugs

This report looks at prescribing trends in primary care for antibacterial drugs at SICBL and ICB level with particular focus on prescribing volume of antibacterial agents such as cephalosporins, quinolones, macrolides and tetracyclines. Prescribing data is weighted with STAR-PU prescribing measures, and incorporates C. difficile rates and non-medical prescribing. If you have any queries about […]